GET THE APP

..

Journal of Cancer Clinical Trials

ISSN: 2577-0535

Open Access

Volume 2, Issue 2 (2017)

Review Article Pages: 1 - 3

Pediatric Leukemia: Diagnosis to Treatment–A Review

Samantha C. Bernard, Ehab H. Abdelsamad, Paisley A. Johnson, Daniel L. Chapman and Madhukiran Parvathaneni

Leukemia is cancer of the blood and bone marrow, it is the most common cancer found in children and is found to be more than one fourth of pediatric cancers. It causes white blood cells to become abnormal and the body to become weak. This deficiency in the immune system reduces the body's ability to fight infection or simple airborne illnesses, causing extensive treatment of common pathogens and cancer treatment. The present review covers all topics, from diagnosis to treatment of pediatric leukemia, as well as the stages of growth and physiological changes throughout the process. As leukemia has a high mortality rate the chances of survival are low. Discussion on survival rate will be breached and thoroughly deciphered. We also included the topic of treatment and at which point patients may be considered terminal or advanced. By approaching these points, we better understand leukemia (from a scientific standpoint) and its properties throughout the course of treatment.

Review Article Pages: 1 - 3

Immunotherapy: An Answer for Cancer?

C.V. Patel and V.C. Patel

Objective: Conventional treatment offers no solution to advanced cancer patients in developing countries like India. The aim was to find out if the history of Indian and world medicine reveals any answers for such patients.

Methods: The evidence based therapies tried in clinical cases were recorded from world literature on oncology. The only selection criterion was advance cancer patients in whom conventional treatment was tried and failed.

Results: The parameters of results were mainly a) palliation of symptoms b) increase in life span c) disease free survival. The methods tried in literature were used in our patients and results of original authors and our results were compared and recorded. Pathophysiology of each method was discussed independently.

Conclusions: Best results were obtained where conventional destructive methods were complimented with boost to patient’s immunity. Principles of Dr Jenner’s vaccine therapy were utilised. Though histologically, patients may suffer from one pathology (i.e. Gastric cancer), each patient may give different immunological response to immunotherapy. Hence each patient was immunological stimulated against his own tumour by totally or partially destroying his tumour in situ with physical agents like patients own urine, or heat, anoxia and powerful allergens from plant extracts. Our survival rates are 3% over 10 years of disease control. In other 97% patients, about 30% had substantial palliation. Rest died at home shortly and follow up was not possible.

Research Article Pages: 1 - 5

Dubious Action of Atrazine as an Endocrine Disrupting Agent: An In silico Approach

Shailima Rampogu, R.D. Neelima Vardhani, SSNP Ekke and Rajesh Goud Gajula

Atrazine is chlorine containing chemical compound which is widely used as an herbicide. However, upon its entry into the human body, it is known to affect several organs and their functions. Additionally, atrazine also represses photosynthesis in plants and causes serious disorders in animals as well. One of the most challenging actions of atrazine is its action has an endocrine disruptor. The present article makes an effort to delineate on the binding affinity of the herbicide to two human hormone receptors, and also to understand its endocrine disrupting capability adapting the computational methods.

Google Scholar citation report
Citations: 95

Journal of Cancer Clinical Trials received 95 citations as per Google Scholar report

Journal of Cancer Clinical Trials peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward